1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 14 , 15 , 15 , 16 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 25 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 30 , 34 , 36 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 41 , 12 , 43 , 44 , 45 , 46 , 47 , 10 , 11 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 4 , 5 , 4 , 5 , 9 , 1 , 1 , 59 , 17 , 23 , 60 , 61 , 61 , 62 , 63 , 21 , 7 , 7 , 22 , 64 , 65 , 43 , 2 , 4 , 4 , 5 , 4 , 5 , 2 , 66 , 65 , 67 , 62 , 38 , 37 , 39 , 40 , 30 , 35 , 68 , 33 , 69 , 18 , 6 , 70 , 71 , 4 , 5 , 72 , 2 , 73 , *
      Journal of Clinical and Translational Hepatology
      XIA & HE Publishing Inc.
      Hepatitis C virus, Liver cirrhosis, Hepatocellular carcinoma, Genotype, DAA, REAL-C

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Aims

          As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination goal. This study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with all HCV GTs, focusing on GT3 and GT6.

          Methods

          We analyzed the sustained virological response (SVR12) of 15,849 chronic hepatitis C patients from 39 Real-World Evidence from the Asia Liver Consortium for HCV clinical sites in Asia Pacific, North America, and Europe between 07/01/2014–07/01/2021.

          Results

          The mean age was 62±13 years, with 49.6% male. The demographic breakdown was 91.1% Asian (52.9% Japanese, 25.7% Chinese/Taiwanese, 5.4% Korean, 3.3% Malaysian, and 2.9% Vietnamese), 6.4% White, 1.3% Hispanic/Latino, and 1% Black/African-American. Additionally, 34.8% had cirrhosis, 8.6% had hepatocellular carcinoma (HCC), and 24.9% were treatment-experienced (20.7% with interferon, 4.3% with direct-acting antivirals). The largest group was GT1 (10,246 [64.6%]), followed by GT2 (3,686 [23.2%]), GT3 (1,151 [7.2%]), GT6 (457 [2.8%]), GT4 (47 [0.3%]), GT5 (1 [0.006%]), and untyped GTs (261 [1.6%]). The overall SVR12 was 96.9%, with rates over 95% for GT1/2/3/6 but 91.5% for GT4. SVR12 for GT3 was 95.1% overall, 98.2% for GT3a, and 94.0% for GT3b. SVR12 was 98.3% overall for GT6, lower for patients with cirrhosis and treatment-experienced (TE) (93.8%) but ≥97.5% for treatment-naive patients regardless of cirrhosis status. On multivariable analysis, advanced age, prior treatment failure, cirrhosis, active HCC, and GT3/4 were independent predictors of lower SVR12, while being Asian was a significant predictor of achieving SVR12.

          Conclusions

          In this diverse multinational real-world cohort of patients with various GTs, the overall cure rate was 96.9%, despite large numbers of patients with cirrhosis, HCC, TE, and GT3/6. SVR12 for GT3/6 with cirrhosis and TE was lower but still excellent (>91%).

          Graphical abstract

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          EASL recommendations on treatment of hepatitis C: Final update of the series☆

          Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

            As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

              Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends.
                Bookmark

                Author and article information

                Journal
                J Clin Transl Hepatol
                J Clin Transl Hepatol
                JCTH
                Journal of Clinical and Translational Hepatology
                XIA & HE Publishing Inc.
                2225-0719
                2310-8819
                28 July 2024
                17 June 2024
                : 12
                : 7
                : 646-658
                Affiliations
                [1 ]Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
                [2 ]Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA
                [3 ]Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan
                [4 ]Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung
                [5 ]Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung
                [6 ]Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
                [7 ]Gastroenterology & Hepatology, Changi General Hospital, Singhealth, Singapore
                [8 ]Singhealth Duke-NUS Medicine Academic Clinical Program, Singapore
                [9 ]Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan
                [10 ]Department of Internal Medicine, Hanyang University, College of Medicine, Seoul, Korea
                [11 ]Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea
                [12 ]Department of Hepatology, The Third People's Hospital of Kunming City, Kunming, Yunnan, China
                [13 ]Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
                [14 ]Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
                [15 ]Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung
                [16 ]Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                [17 ]Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan
                [18 ]Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan
                [19 ]Department of Transfusion Medicine and Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
                [20 ]San Jose Gastroenterology, San Jose, CA, USA
                [21 ]Gastroenterology & Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania
                [22 ]Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA, USA
                [23 ]Department of Gastroenterology, Good Gang-An Hospital, Busan, Korea
                [24 ]Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan
                [25 ]Liver Center, Saga University Hospital, Saga, Japan
                [26 ]Division of Metabolism and Endocrinology, Saga University Faculty of Medicine, Saga, Japan
                [27 ]Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Chiba, Japan
                [28 ]2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan
                [29 ]Locomedical General Institute, Locomedical Eguchi Hospital, Saga, Japan
                [30 ]Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
                [31 ]Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
                [32 ]Department of Gastroenterology and Hepatology, The Second People's Hospital of Tianjin, Tianjin, China
                [33 ]Department of Infectious Diseases, Henan Provincial People’s Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China
                [34 ]Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin, China
                [35 ]Department of Medicine, The University of Hong Kong, Hong Kong, China
                [36 ]Department of Hepatology, Zhejiang Provincial People’s Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang, China
                [37 ]Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
                [38 ]Center of liver diseases, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, China
                [39 ]Division of Gastroenterology and Hepatology, National University Hospital, Singapore
                [40 ]Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
                [41 ]Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
                [42 ]State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
                [43 ]Digestive Health Associates of Texas, Dallas, TX, USA
                [44 ]Taihaku Avenue Clinic, Fukuoka, Japan
                [45 ]Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
                [46 ]Department of Internal Medicine, Haradoi Hospital, Fukuoka, Japan
                [47 ]Hepatology Clinic, Kajiwara Clinic, Kitakyushu, Japan
                [48 ]Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea
                [49 ]Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan
                [50 ]Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan
                [51 ]Department of Internal Medicine, Hanyang University, College of Medicine, Guri Hospital, Guri, Korea
                [52 ]Division of Hepatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
                [53 ]Departments of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
                [54 ]Department of Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan
                [55 ]Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan
                [56 ]Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan
                [57 ]Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan
                [58 ]Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan
                [59 ]Division of Gastoroentelorogy, Nippon Medcal School Chiba Hokusoh Hospital, Chiba, Japan
                [60 ]Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan
                [61 ]Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan
                [62 ]Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin, China
                [63 ]Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
                [64 ]Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
                [65 ]Liver Diseases Group, Vall d’Hebron Research Institute, Barcelona, Spain
                [66 ]Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
                [67 ]Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d’Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain
                [68 ]State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China
                [69 ]Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Ji’nan, Shandong, China
                [70 ]Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
                [71 ]Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan
                [72 ]School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung
                [73 ]Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA
                Author notes
                [* ] Correspondence to: Mindie H. Nguyen, MD, MAS, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health, Stanford University Medical Center, 780 Welch Road, CJ250K, Palo Alto, CA 94304, USA. ORCID: https://orcid.org/0000-0002-6275-4989. Tel: +1-650-498-6084, E-mail: mindiehn@ 123456stanford.edu .
                [#]

                Contributed equally to this work.

                This study is partially supported by an investigator-initiated research grant (IN-US-334-4309) from Gilead Sciences to Stanford University. The authors independently collected the data, designed and performed all study analyses, and drafted the manuscript. The funding source had no role in the study design, data collection, data analysis or interpretation, report writing, or the decision to submit the paper for publication.

                FJ: Speaker fees: Gilead Sciences, MSD, and Ascletis. Consultancy: Gilead Sciences, MSD. FJ has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2023. YJW: Speaker fees: Gilead Science, AbbVie. Research Grant: Medicine Academic Clinical Program, SingHealth, Singapore. YJW has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2020. HT: Speaker fees: Gilead Science, AbbVie, Eisai, Fujifilm WAKO, Takeda, Kowa, Terumo, Astra Zeneca. VWSW: Consultancy: AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, Visirna. Speaker fees: Abbott, AbbVie, Gilead Sciences, Novo Nordisk, Unilab. Research grants: Gilead Sciences. Stock: Co-founder of Illuminatio Medical Technology Limited. MA: Speakers’ fees: AbbVie, Gilead Sciences. SD: Speakers fees: Gilead Sciences. MFY: Speakers’ fees: Fujirebio Incorporation, Gilead Sciences, Roche, Sysmex Corporation. Consulting or advisory board: AbbVie, Abbott Diagnostics, Aligos Therapeutics, AiCuris, Antios Therapeutics, Arbutus Biopharma, Arrowhead Pharmaceuticals, Assembly Biosciences, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, Fujirebio Incorporation, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Precision BioSciences, Roche, Sysmex Corporation, Tune Therapeutics, Vir Biotechnology and Visirna Therapeutics. Research grant: AbbVie, Assembly Biosciences, Arrowhead Pharmaceuticals, Fujirebio Incorporation, Gilead Sciences, Immunocore, Sysmex Corporation and Roche. MFY has been an Associate Editor of Journal of Clinical and Translational Hepatology since 2021. CW: Research grant: Gilead Sciences. MLYu: Research support (grant) from Abbvie, BMS, Gilead, Merck, and Roche diagnostics. Consultant of Abbvie, BMS, Gilead, Roche, and Roche diagnostics. Speaker of Abbvie, BMS, Eisai, Gilead, Roche, and Roche diagnostics. MLYu has been an Associate Editor of Journal of Clinical and Translational Hepatology since 2023. MHN: Research grants via institution: Pfizer, Enanta, Astra Zeneca, GSK, Delfi, Innogen, Exact Science, CurveBio, Gilead, Vir Biotech, Helio Health, National Cancer Institute, Glycotest. Consulting/Advisory board: Intercept, Exact Science, Gilead, GSK. JL, MLYe, WLC and JFH have been Editorial Board Members of Journal of Clinical and Translational Hepatology since 2022. HR has been an Editor-in-Chief of Journal of Clinical and Translational Hepatology since 2013. The other authors have no conflict of interests related to this publication.

                Guarantor of the article: MHN. Specific author contributions: study design: FJ, ST, and MHN. Data collection: all the authors. Data analysis: ST, FJ and MHN. Data interpretation: all the authors. Drafting of the article: FJ, ST and MHN. Study concept and study supervision: MHN.

                Author information
                https://orcid.org/0000-0002-6275-4989
                Article
                JCTH.2024.00089
                10.14218/JCTH.2024.00089
                11233980
                38993510
                b519a712-2d75-4edc-add6-2f605a5af70c
                © 2024 Authors.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 07 March 2024
                : 08 May 2024
                : 22 May 2024
                Categories
                Original Article

                hepatitis c virus,liver cirrhosis,hepatocellular carcinoma,genotype,daa,real-c

                Comments

                Comment on this article